Ben Nichols

Ben has over 30 years’ experience in the biotechnology industry in a variety of senior commercial and managerial roles. He has managed three companies and has achieved two exits for venture capital share-holders. He was CEO of Haemostatix Ltd in the UK for ten years and led the sale to Ergomed plc in 2016. Haemostatix invented a novel class of peptide-based surgical coagulant, and developed the lead product, PeproStat, to a successful Phase II trial in 169 surgical patients with intra-operative bleeding. Their pipeline product HXP12 ReadyFlow won the Royal Society of Chemistry’s Emerging Technology competition in 2015. Ben is also Chairman of Selentus Science Ltd, a company developing an adhesive technology, TenaTac® for the application of haemostats to surgical wounds.